期刊文献+
共找到5,223篇文章
< 1 2 250 >
每页显示 20 50 100
Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma:Based on muti-omics analysis and vitro assay
1
作者 HONGYUAN LIANG YANQIU LI +1 位作者 YONGGANG QU LINGYUN ZHANG 《Oncology Research》 SCIE 2024年第2期393-407,共15页
Advanced LUAD shows limited response to treatment including immune therapy.With the development of sequencing omics,it is urgent to combine high-throughput multi-omics data to identify new immune checkpoint therapeuti... Advanced LUAD shows limited response to treatment including immune therapy.With the development of sequencing omics,it is urgent to combine high-throughput multi-omics data to identify new immune checkpoint therapeutic response markers.Using GSE72094(n=386)and GSE31210(n=226)gene expression profile data in the GEO database,we identified genes associated with lung adenocarcinoma(LUAD)death using tools such as“edgeR”and“maftools”and visualized the characteristics of these genes using the“circlize”R package.We constructed a prognostic model based on death-related genes and optimized the model using LASSO-Cox regression methods.By calculating the cell death index(CDI)of each individual,we divided LUAD patients into high and low CDI groups and examined the relationship between CDI and overall survival time by principal component analysis(PCA)and Kaplan-Meier analysis.We also used the“ConsensusClusterPlus”tool for unsupervised clustering of LUAD subtypes based on model genes.In addition,we collected data on the expression of immunomodulatory genes and model genes for each cohort and performed tumor microenvironment analyses.We also used the TIDE algorithm to predict immunotherapy responses in the CDI cohort.Finally,we studied the effect of PRKCD on the proliferation and migration of LUAD cells through cell culture experiments.The study utilized the TCGA-LUAD cohort(n=493)and identified 2,901 genes that are differentially expressed in patients with LUAD.Through KEGG and GO enrichment analysis,these genes were found to be involved in a wide range of biological pathways.The study also used univariate Cox regression models and LASSO regression analyses to identify 17 candidate genes that were best associated with mortality prognostic risk scores.By comparing the overall survival(OS)outcomes of patients with different CDI values,it was found that increased CDI levels were significantly associated with lower OS rates.In addition,the study used unsupervised cluster analysis to divide 115 LUAD patients into two distinct clusters with significant differences in OS timing.Finally,a prognostic indicator called CDI was established and its feasibility as an independent prognostic indicator was evaluated by Cox proportional risk regression analysis.The immunotherapy efficacy was more sensitive in the group with high expression of programmed cell death models.Relationship between programmed cell death(PCD)signature models and drug reactivity.After evaluating the median inhibitory concentration(IC50)of various drugs in LUAD samples,statistically significant differences in IC50 values were found in cohorts with high and low CDI status.Specifically,Gefitinib and Lapatinib had higher IC50 values in the high-CDI cohort,while Olaparib,Oxaliplatin,SB216763,and Axitinib had lower values.These results suggest that individuals with high CDI levels are sensitive to tyrosine kinase inhibitors and may be resistant to conventional chemotherapy.Therefore,this study constructed a gene model that can evaluate patient immunotherapy by using programmed cell death-related genes based on muti-omics.The CDI index composed of these programmed cell death-related genes reveals the heterogeneity of lung adenocarcinoma tumors and serves as a prognostic indicator for patients. 展开更多
关键词 lung adenocarcinoma Programmed cell death Iron-death drug sensitivity Cancer therapy
下载PDF
Experimental study on effect of recombinant human growth hormone combined with chemotherapy on stomach neoplasms implanted in nude mice 被引量:1
2
作者 Fangfang Shi Suyi Li 《The Chinese-German Journal of Clinical Oncology》 CAS 2007年第1期27-31,共5页
Objective: To investigate the effect of different doses of recombined growth hormone (rhGH) on stomach neo- plasms implanted in nude mice, and its efficacy in combining with chemotherapy (flurouracil, 5-FU). Methods: ... Objective: To investigate the effect of different doses of recombined growth hormone (rhGH) on stomach neo- plasms implanted in nude mice, and its efficacy in combining with chemotherapy (flurouracil, 5-FU). Methods: Human stom- ach neoplasms model was established in nude mice. The nude mice were divided into control group, moderate-dose of rhGH group, low-dose rhGH group, 5-FU group, moderate-dose rhGH/5-FU group, and low-dose rhGH/5-FU group. The results of each group were observed after ten days. Results: After therapy, the body mass of rhGH groups was significantly increased compared with control group (P<0.05), the body mass of rhGH/5-FU groups was significantly increased compared with 5-FU group (P<0.05), but it was no significant difference between rhGH/5-FU groups and control group (P>0.05). The average tumor mass and volume of rhGH groups were not significantly increased compared with control group (P>0.05), but they were significantly reduced in 5-FU group and rhGH/5-FU groups (P<0.05). They were no significant difference between rhGH/5- FU groups and 5-FU group (P>0.05). After treatment, the percentages of S, G0/G1 and G2/M phases and proliferation index (PI) were not significantly changed in rhGH groups compared with control group (P>0.05), and the same with rhGH/5-FU groups compared with 5-FU group (P>0.05). The difference caused by dose of rhGH was not significant. Conclusion: rhGH enhances body mass, does not stimulate tumor growth, and has no adverse effects on tumor bearing nude mice. Combined with flurouracil, rhGH does not influence the efficacy of chemotherapy, and has no effect on tumor cell cycle kinetics. 展开更多
关键词 stomach neoplasms/drug therapy mice nude recombined human growth hormone
下载PDF
Postoperative chemoradiotherapy with capecitabine and oxaliplatin vs.capecitabine for pathological stage N2 rectal cancer
3
作者 Ning Li Yuan Zhu +20 位作者 Luying Liu Yanru Feng Wenling Wang Jun Wang Hao Wang Gaofeng Li Yuan Tang Chen Hu Wenyang Liu Hua Ren Shulian Wang Weihu Wang Yongwen Song Yueping Liu Hui Fang Yu Tang Ningning Lu Bo Chen Shunan Qi Yexiong Li Jing Jin 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2024年第5期577-586,共10页
Objective:Several studies have been conducted on the effects and toxicity of adding oxaliplatin to fluorouracilbased or capecitabine-based chemoradiotherapy(CRT)regimens as significantly increasing the toxic response ... Objective:Several studies have been conducted on the effects and toxicity of adding oxaliplatin to fluorouracilbased or capecitabine-based chemoradiotherapy(CRT)regimens as significantly increasing the toxic response without benefit to survival.In this study,we further explored the role of these two postoperative CRT regimens in patients with pathological stage N2 rectal cancer.Methods:This study was a subgroup analysis of a randomized clinical trial.A total of 180 patients with pathological stage N2 rectal cancer were eligible,85 received capecitabine with radiotherapy(RT),and 95 received capecitabine and oxaliplatin with RT.Patients in both groups received adjuvant chemotherapy[capecitabine and oxaliplatin(XELOX);or fluorouracil,leucovorin,and oxaliplatin(FOLFOX)]after CRT.Results:At a median follow-up of 59.2[interquartile range(IQR),34.0−96.8]months,the three-year diseasefree survival(DFS)was 53.3%and 64.9%in the control group and the experimental group,respectively[hazard ratio(HR),0.63;95%confidence interval(95%CI),0.41−0.98;P=0.04].There was no significant difference between the groups in overall survival(OS)(HR,0.62;95%CI,0.37−1.05;P=0.07),the incidence of locoregional recurrence(HR,0.62;95%CI,0.24−1.64;P=0.33),the incidence of distant metastasis(HR,0.67;95%CI,0.42−1.06;P=0.09)and grade 3−4 acute toxicities(P=0.78).For patients with survival longer than 3 years,the conditional overall survival(COS)was significantly better in the experimental group(HR,0.39;95%CI,0.16−0.96;P=0.03).Conclusions:Our results indicated that adding oxaliplatin to capecitabine-based postoperative CRT is safe and effective in patients with pathological stage N2 rectal cancer. 展开更多
关键词 CHEMORADIOtherapy OXALIPLATIN CAPECITABINE rectal neoplasms drug therapy RADIOtherapy treatment outcome
下载PDF
Analysis of the Efficacy,Progression-Free Survival,and Safety of Anlotinib in Advanced Lung Cancer Treatment
4
作者 Jie Shen Cheng Meng +2 位作者 Xiaoyan Zhang Rong Lei Liyun Hao 《Proceedings of Anticancer Research》 2024年第1期105-111,共7页
Objective:To analyze the clinical efficacy,progression-free survival,and safety of anlotinib in the treatment of advanced lung cancer.Methods:A retrospective analysis was conducted using data from 60 patients with adv... Objective:To analyze the clinical efficacy,progression-free survival,and safety of anlotinib in the treatment of advanced lung cancer.Methods:A retrospective analysis was conducted using data from 60 patients with advanced lung cancer treated with anlotinib from May 2019 to May 2021.This analysis aimed to comprehensively evaluate the clinical efficacy,progression-free survival,and adverse reactions of anlotinib.Results:The median progression-free survival(PFS)for the 60 patients was 5.79 months,with an overall response rate(ORR)of 21%and a disease control rate(DCR)of 90%.In the first-line group,the median PFS was 6.20 months,ORR was 76.92%,and DCR was 84.61%.The second-line group showed a median PFS of 6.30 months,ORR of 28.57%,and DCR of 90.48%.In the third-line group,the median PFS was 5.34 months,ORR was 19.23%,and DCR was 92.30%.The single-agent group exhibited a median PFS of 5.09 months,ORR of 23.33%,and DCR of 76.67%.In the combination group,the median PFS was 6.53 months,ORR was 46.67%,and DCR was 100%.The combination group demonstrated a significantly higher medication effect than the single-drug group,and adverse drug reactions were mostly grade 1-2.Conclusion:Anlotinib exhibits a better disease control rate and survival benefit in the treatment of advanced lung cancer.The combination effect is superior to monotherapy,with relatively controllable adverse effects. 展开更多
关键词 Anlotinib Advanced lung cancer Vascular targeted therapy Recent efficacy drug safety
下载PDF
Gene Polymorphisms and Chemotherapy in Non-small Cell Lung Cancer 被引量:4
5
作者 Kayo OSAWA 《中国肺癌杂志》 CAS 2009年第8期837-840,共4页
The phamacogenetics is being used to predict whether the selected chemotherapy will be really effective and tolerable to the patient. Irinotecan,oxidized by CYP3A4 to produce inactive compounds,is used for treatment o... The phamacogenetics is being used to predict whether the selected chemotherapy will be really effective and tolerable to the patient. Irinotecan,oxidized by CYP3A4 to produce inactive compounds,is used for treatment of various cancers including advanced non small cell lung cancer (NSCLC) patients. CYP3A4*16B polymorphism was associated with decreased metabolism of irrinotecan. Irinotecan is also metabolized by carboxylesterase to its principal active metabolite,SN-38,which is subsequently glucuronidated by UGT1As to form the inactive compound SN-38G. UGT1A1*28 and UGT1A1*6 polymorphisms were useful for predicting severe toxicity with NSCLC patients treated with irinotecan-based chemotherapy. Platinum-based compounds (cisplatin,carboplatin) are being used in combination with new cytotoxic drugs such as gemcitabine,paclitaxel,docetaxel,or vinorelbine in the treatment of advanced NSCLC. Cisplatin activity is mediated through the formation of cisplatin-DNA adducts. Gene polymorphisms of DNA repair factors are therefore obvious candidates for determinants of repair capacity and chemotherapy efficacy. ERCC1,XRCC1 and XRCC3 gene polymorphisms were a useful marker for predicting better survival in advanced NSCLC patients treated with platinum-based chemotherapy. XPA and XPD polymorphisms significantly increased response to platinum-based chemotherapy. These DNA repair gene polymorphisms were useful as a predictor of clinical outcome to the platinum-based chemotherapy. EGFR kinase inhibitors induce dramatic clinical responses in NSCLC patients with advanced disease. EGFR gene polymorphism in intron 1 contains a polymorphic single sequence dinucleotide repeat (CA-SSR) showed a statistically significant correlation with the gefitinib response and was appeared to be a useful predictive marker of the development of clinical outcome containing skin rashes with gefitinib treatment. The other polymorphisms of EGFR were also associated with increased EGFR promoter activity. EGFR gene mutations and polymorphisms were also associated with EGFR kinase inhibitors response and toxicity. 展开更多
关键词 非小细胞肺癌 基因多态性 化学疗法 疗效
下载PDF
EXPRESSION AND REVERSION OF DRUG RESISTANCE-AND APOPTOSIS-RELATED GENES OF A DDP-RESISTANT LUNG ADENOCARCINOMA CELL LINE 被引量:1
6
作者 王洁 张叙仪 蒋薇 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2000年第2期79-86,共8页
Objective: To investigate the co-expression of drug resistance- and apoptosis-related genes of cisplatin (CDDP)-selected lung adenocarcinoma cell line A 549 DDP for compared to the parental cell line A549, and reverse... Objective: To investigate the co-expression of drug resistance- and apoptosis-related genes of cisplatin (CDDP)-selected lung adenocarcinoma cell line A 549 DDP for compared to the parental cell line A549, and reverse of drug resistance by antisense s-oligodeoxynucleotides (S-ODNs) of differentially expressed genes. Methods: Sense and antisense S-ODN were transferred into A 549 DDP cells by lipofectin. The expression of drug resistance and apoptosis related genes was examined by RT-PCR, immunocytochemistry and flow cytometry, respectively. Apoptostic cells were identified by DNA electrophoresis and terminal deoxynucleotidyl transferase (TdT)-mediated biotin dUTP nick end-labeling(TUNEL). Drug resistance of tumor cells was detected by a cell viability (MTT) assay. Results: The expression of bcl-2 was positive and that of multidrug resistance-associated protein (MRP) at mRNA and protein level was increased in A 549 DDP compared to A549 cells. MDR1, c-myc and topoisomeras II (TOPO II) were similarly co-expressed in two cell lines. Both cell lines were negative for c-erbB-2 expression. In A 549 DDP cells, the expression of bcl-2 and MRP was significantly inhibited by their respective antisense S-ODNs. Antisense S-ODNs could also decrease significantly drug resistance of A 549 DDP cells to CDDP by promoting cell apoptosis. Conclusion: Both intrinsic and acquired drug resistance were involved in co-expression of multiple MDR-related genes in lung adenocarcinoma. Cooperation of bcl-2 and MRP genes appeared to play an important action to confer the resistance of A 549 DDP cells to CDDP. Their antisense S-ODNs are responsible for the decrease of drug resistance of this cell line by promoting apoptosis. 展开更多
关键词 lung neoplasm A549 and A 549 DDP cell lines Apoptosis Antisense oligoxynucleotide drug resistance-gene
下载PDF
Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations 被引量:1
7
作者 Guowei ZHANG Ruirui CHENG +7 位作者 Yuanyuan NIU Huijuan WANG Xiangtao YAN Mina ZHANG Xiaojuan ZHANG Jinpo YANG Chunhua WEI Zhiyong MA 《中国肺癌杂志》 CAS CSCD 北大核心 2022年第9期651-657,共7页
Background and objective:Epidermal growth factor receptor(EGFR)mutations are often associated with non-EGFR genetic alterations,which maybe a reason for the poor efficacy of EGFR tyrosine kinase inhibitors(TKIs).Here ... Background and objective:Epidermal growth factor receptor(EGFR)mutations are often associated with non-EGFR genetic alterations,which maybe a reason for the poor efficacy of EGFR tyrosine kinase inhibitors(TKIs).Here we conducted this study to explore whether EGFR-TKIs combined with chemotherapy would benefit advanced lung adenocarcinoma patients with both sensitive EGFR mutation and concomitant non-EGFR genetic alterations.Materials and methods:Cases of advanced lung adenocarcinoma with EGFR mutation combined with concomitant nonEGFR genetic alterations were retrospectively collected.And the patients were required to receive first-line EGFR-TKIs and chemotherapy combination or EGFR-TKIs monotherapy.Demographic,clinical and pathological data were collected,and the electronic imaging data were retrieved to evaluate the efficacy and time of disease progression.Survival data were obtained through face-to-face or telephone follow-up.The differences between the two groups in objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS)and overall survival(OS)were investigated.Results:107 patients were included,including 63 cases in the combination group and 44 cases in the monotherapy group.The ORR were 78%and 50%(P=0.003),and DCR were 97%and 77%(P=0.002),respectively.At a median follow-up of 13.7 mon,a PFS event occurred in 38.1%and 81.8%of patients in the two groups,with median PFS of18.8 mon and 5.3 mon,respectively(P<0.000,1).Median OS was unreached in the combination group,and 27.8 mon in the monotherapy group(P=0.31).According to the Cox multivariate regression analysis,combination therapy was an independent prognostic factor of PFS.Conclusion:In patients with EGFR-mutant advanced lung adenocarcinoma with concomitant non-EGFR genetic alterations,combination of TKIs and chemotherapy was significantly superior to EGFR-TKIs monotherapy,which should be the preferred treatment option. 展开更多
关键词 lung neoplasms EGFR mutation Concomitant genetic alteration Targeted therapy CHEMOtherapy
下载PDF
Expression and Prognostic Significance of Multidrug Resistance Associated Protein (MRP) Gene in Non-small Cell Lung Cancer by in Site Hybridization 被引量:1
8
作者 单根法 钟竑 +4 位作者 张辅贤 李国庆 隆桂麟 顾鹤定 戚晓敏 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2000年第3期63-66,共4页
Objective: To study on the effect of MRP gene overexpression on prognosis of patients with non-small lung cancer (NSCLC). Methods: Paraffin-embedded tissues from 47 cases of NSCLC who had undergone radical tumor rese... Objective: To study on the effect of MRP gene overexpression on prognosis of patients with non-small lung cancer (NSCLC). Methods: Paraffin-embedded tissues from 47 cases of NSCLC who had undergone radical tumor resection were examined for expression of MRP gene mRNA by in situ hybridization using labelled digoxigenin probes combined with immunohistochemistry. All the patients were retrospectively followed-up. Results: All of the 47 lung cancer specimens were found to have overexpression of MRP gene mRNA. It was significantly correlated with patients' survival time, response to chemotherapy, recurrence or metastases after surgery, but was not correlated with histology, tumor size, node status, TNM stage, degree of differentiation, age and sex. Conclusion: Overexpression of MRP gene is a marker of prognostic significance in patients with NSCLC. 展开更多
关键词 lung neoplasms multi-drug resistance MRP gene PROGNOSIS
下载PDF
The Therapeutic Effects of the Radiotherapy Plus TCM Treatment Observed in Senile Non-Parvicellular Lung Cancer Patients at the Late Stage
9
作者 蓝孝筑 姜玉华 王薇 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2003年第1期32-34,共3页
47 senile non-parvicellular lung cancer patients at stage Ⅲ or Ⅳ were randomly divided into a treatment group (26 cases) treated by radiotherapy plus traditional Chinese medicine (TCM) and a control group (21 cases)... 47 senile non-parvicellular lung cancer patients at stage Ⅲ or Ⅳ were randomly divided into a treatment group (26 cases) treated by radiotherapy plus traditional Chinese medicine (TCM) and a control group (21 cases) treated only by radiotherapy for observation of the therapeutic effects.The patients in the treatment group orally took Chinese medicine during and after the radiotherapy.There was no obvious difference in short-term therapeutic effects between the two groups,but the long-term curative effects in the treatment group was obviously superior to that in the control group (P<0.05 or P<0.01).Conclusion:radiotherapy plus TCM can prolong the survival period for senile non-parvicellular lung cancer patients. 展开更多
关键词 PHYTOtherapy Aged Carcinoma Non-Small-Cell lung Carcinoma Squamous Cell Combined Modality therapy drugs Chinese Herbal Female Follow-Up Studies Humans lung neoplasms Male
下载PDF
Immunotherapy for recurrent hepatocellular carcinoma 被引量:1
10
作者 Ahan Bhatt Jennifer Wu 《World Journal of Gastroenterology》 SCIE CAS 2023年第15期2261-2271,共11页
Hepatocellular carcinoma(HCC)is presented frequently in late stages that are not amenable for curative treatment.Even for patients who can undergo resection for curative treatment of HCC,up to 50%recur.For patients wh... Hepatocellular carcinoma(HCC)is presented frequently in late stages that are not amenable for curative treatment.Even for patients who can undergo resection for curative treatment of HCC,up to 50%recur.For patients who were not exposed to systemic therapy prior to recurrence,recurrence frequently cannot be subjected to curative therapy or local treatments.Such patients have several options of immunotherapy(IO).This includes programmed cell death protein 1(PD-1)and cytotoxic T-lymphocyte associated protein 4 treatment,combination of PD-1 and vascular endothelial growth factor inhibitor or single agent PD-1 therapy when all other options are deemed inappropriate.There are also investigational therapies in this area that explore either PD-1 and tyrosine kinase inhibitors or a novel agent in addition to PD-1 with vascular endothelial growth factor inhibitors.This minireview explored IO options for patients with recurrent HCC who were not exposed to systemic therapy at the initial diagnosis.We also discussed potential IO options for patients with recurrent HCC who were exposed to first-line therapy with curative intent at diagnosis. 展开更多
关键词 Liver neoplasms Immune checkpoint blockade Combination drug therapy PD-1-PD-L1 blockade CTLA-4 inhibitor
下载PDF
Missing the Target?—Targeted Therapy in Small Cell Lung Cancer
11
作者 Karin R. Purshouse 《Advances in Lung Cancer》 2014年第3期53-61,共9页
Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. Thi... Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development. 展开更多
关键词 ONCOLOGY Small Cell lung Cancer TARGETED therapy drug Development
下载PDF
Bioinformatics Identification of ZNFs/LINC00520/miR-181d/BCL2 Axis as a Novel Network in Cisplatin-Resistant Lung Adenocarcinoma Cells
12
作者 Ying Xu Na Guo +8 位作者 Jinghan Guo Dongze Wang Qian Xu Xiangling Li Zhengxin Zhang Hongbin Yang Ruxing Wang Xiurong Zhao Lei Liu 《American Journal of Molecular Biology》 CAS 2023年第1期67-93,共27页
Background: Resistance to cisplatin (DDP) leads to poor prognosis in patients with Lung Adenocarcinoma (LUAD) and limits its clinical application. It has been confirmed that autophagy promotes chemoresistance and, the... Background: Resistance to cisplatin (DDP) leads to poor prognosis in patients with Lung Adenocarcinoma (LUAD) and limits its clinical application. It has been confirmed that autophagy promotes chemoresistance and, therefore, novel strategies to reverse chemoresistance by regulating autophagy are desperately needed. Methods: The differentially expressed lncRNAs (DElncRNAs), miRNAs (DEmiRNAs), and mRNAs (DEmRNAs) between A549 and A549/DDP cell lines were identified using the limma package in R, after gene expression profiles were obtained from Gene Expression Omnibus (GEO) database. By combining Autophagy-Related Genes (ARGs) from Human Autophagy Database (HADb), the interactions lncRNA-miRNAs and the interactions miRNAs-mRNAs respectively predicted by miRcode and miRDB/Targetscan database, the autophagy-related ceRNA network was constructed. Then, extraction of ceRNA subnetwork and Cox regression analyses were performed. A prognosis-related ceRNA subnetwork was constructed, and the upstream Transcription Factors (TFs) regulating lncRNAs were predicted by the JASPAR database. Finally, the expression patterns of candidate genes were further verified by quantitative real-time polymerase chain reaction (qRT-PCR) experiments. Results: A total of 3179 DEmRNAs, 180 DEmiRNAs, and 160 DElncRNAs were identified, and 35 DEmRNAs were contained in the HADb. Based on the ceRNA hypothesis, we established a ceRNA network, including 10 autophagy-related DEmRNAs, 9 DEmiRNAs, and 14 DElncRNAs. Then, LINC00520, miR-181d, and BCL2 were identified to construct a risk score model, which was confirmed to be a well-predicting prognostic factor. Furthermore, 5 TF ZNF family members were predicted to regulate LINC00520, whereas the RT-PCR results showed that the 5 ZNFs were consistent with the bioinformatics analysis. Finally, a ZNF regulatory LINC00520/miR-181d/BCL2 ceRNA subnetwork was constructed. Conclusions: An ZNFs/LINC00520/miR-181d/BCL2 axis as a novel network in DDP-resistant LUAD has been constructed successfully, which may provide potential therapeutic targets for LUAD. 展开更多
关键词 Computational Biology CISPLATIN drug Resistance AUTOPHAGY lung neoplasms
下载PDF
肝癌靶向联合免疫治疗耐药后的二线治疗方案研究进展 被引量:4
13
作者 张天奇 曹钰哲 +1 位作者 左孟轩 顾仰葵 《临床肝胆病杂志》 CAS 北大核心 2024年第2期386-390,共5页
近年来,靶向和免疫单药及联合治疗晚期肝癌的临床研究为一线用药方案选择提供了丰富的疗效与安全性证据。然而,对于肝癌二线治疗方案的选择,目前各项临床指南尚无统一意见,原因在于现有循证医学证据局限于索拉非尼失败后的选择,而对于... 近年来,靶向和免疫单药及联合治疗晚期肝癌的临床研究为一线用药方案选择提供了丰富的疗效与安全性证据。然而,对于肝癌二线治疗方案的选择,目前各项临床指南尚无统一意见,原因在于现有循证医学证据局限于索拉非尼失败后的选择,而对于新的一线方案,如靶向免疫联合治疗肝癌耐药后的二线治疗方案,依然缺乏高证据等级的临床试验结论。本文回顾了目前临床试验研究结果,根据药物作用的不同机制,对靶向免疫一线治疗耐药后肝癌二线治疗方案的研究进行了归纳,并系统总结近年研究进展。对于一线靶免联合治疗耐药的肝癌患者,靶向联合治疗、免疫双抗治疗均有望提高疗效、改善生存,未来还需更多前瞻性临床研究数据,为靶免联合治疗耐药的肝癌患者提供有效、安全的治疗方案。 展开更多
关键词 肝细胞 药物疗法 抗药性 肿瘤
下载PDF
垂体催乳素瘤的临床特点及诊治要点更新--基于《2022版ICCE/AME垂体催乳素瘤临床实践共识》解读 被引量:3
14
作者 谭惠文 李丹婷 余叶蓉 《中国全科医学》 北大核心 2024年第6期650-655,共6页
垂体催乳素瘤是一种由垂体催乳素细胞瘤过量合成和分泌催乳素引起的神经内分泌疾病,垂体催乳素瘤的规范化诊疗对于恢复并维持患者的正常垂体功能并提高其生活质量具有重要意义。2022年1月,《欧洲内分泌杂志》发布了国际临床内分泌学分会... 垂体催乳素瘤是一种由垂体催乳素细胞瘤过量合成和分泌催乳素引起的神经内分泌疾病,垂体催乳素瘤的规范化诊疗对于恢复并维持患者的正常垂体功能并提高其生活质量具有重要意义。2022年1月,《欧洲内分泌杂志》发布了国际临床内分泌学分会(ICCE)与意大利临床内分泌学家协会(AME)关于垂体催乳素瘤的临床实践最新共识申明——《2022版ICCE/AME垂体催乳素瘤临床实践共识》(简称2022版ICCE/AME新共识)。2022版ICCE/AME新共识立足最新循证医学证据,对于垂体催乳素瘤的临床诊治问题进行系统性阐述、分析和建议。本文围绕2022版ICCE/AME新共识关于垂体催乳素瘤的诊断、治疗、特殊人群、多巴胺激动剂抵抗及侵袭性疾病等诊治要点更新进行解读,希望有助于全科医生及内分泌专科医生对于垂体催乳素瘤的认识,为其临床实践的规范化诊疗提供参考。 展开更多
关键词 催乳素瘤 垂体肿瘤 高催乳素血症 指南 催乳素 多巴胺激动剂 药物治疗
下载PDF
工程化外泌体在肺癌治疗中的研究进展
15
作者 杨婉玲 顾岩 《中国肺癌杂志》 CAS CSCD 北大核心 2024年第7期535-540,共6页
非小细胞肺癌最佳的治疗方式为早期手术治疗,而大部分肺癌发现时已为晚期。治疗方式以药物及放射治疗为主。但上述治疗方式出现耐药或疗效不显著是不可避免的,因此,针对肺癌的治疗迫切需要更多的手段。研究证实,工程化外泌体在心血管系... 非小细胞肺癌最佳的治疗方式为早期手术治疗,而大部分肺癌发现时已为晚期。治疗方式以药物及放射治疗为主。但上述治疗方式出现耐药或疗效不显著是不可避免的,因此,针对肺癌的治疗迫切需要更多的手段。研究证实,工程化外泌体在心血管系统疾病、肿瘤、组织再生与修复等领域具有良好的临床应用潜能。本文总结了国内外工程化外泌体在肺癌治疗中的应用。 展开更多
关键词 工程化外泌体 靶向递送 肺肿瘤 基因治疗 肿瘤微环境
下载PDF
免疫细胞及炎症因子对晚期肺癌一线化疗效果的预测价值
16
作者 卢超 胡志清 吴亚斌 《医学临床研究》 CAS 2024年第5期750-753,共4页
【目的】探讨T淋巴细胞亚群、肿瘤浸润T淋巴细胞(Tils)及炎症因子对晚期肺癌一线化疗效果的预测价值。【方法】检测98例首诊TNM分期为Ⅲ/Ⅳ期的非小细胞肺腺癌患者的血清白细胞介素1α(IL-1α)、IL-6、IL-17、γ-干扰素(INF-γ)水平及T... 【目的】探讨T淋巴细胞亚群、肿瘤浸润T淋巴细胞(Tils)及炎症因子对晚期肺癌一线化疗效果的预测价值。【方法】检测98例首诊TNM分期为Ⅲ/Ⅳ期的非小细胞肺腺癌患者的血清白细胞介素1α(IL-1α)、IL-6、IL-17、γ-干扰素(INF-γ)水平及T淋巴细胞亚群CD4^(+)T、CD8^(+)T、调节性T细胞、CD57^(+)细胞、Granzyme B^(+)细胞、CD45RO^(+)细胞比例;所有患者均接受紫杉醇注射液+顺铂化疗,治疗4个周期后评定疗效,并据此分为有效组和无效组,分析化疗无效的影响因素及预测疗效的有效标志物。【结果】化疗后,98例患者中69例化疗有效,29例无效。无效组患者淋巴结转移占比及调节性T细胞、IL-1α表达水平均高于有效组(P<0.05),CD57^(+)细胞、CD45RO^(+)细胞比例均低于有效组(P<0.05)。多因素逐步Logistic回归分析结果显示,调节性T细胞、IL-1α水平高是肺癌患者化疗无效的危险因素(P<0.05),CD57^(+)细胞、CD45RO^(+)细胞比例高是保护因素(P<0.05)。受试者工作特征(ROC)曲线分析显示,调节性T细胞、CD57^(+)细胞、CD45RO^(+)细胞、IL-1α水平预测化疗效果的灵敏度分别为82.76%、86.21%、89.66%、93.10%,四者联合的灵敏度、特异度和曲线下面积(AUC)分别为82.76%、97.10%、0.957。【结论】T淋巴细胞亚群、Tils及炎症因子水平与晚期肺癌治疗效果密切相关,其可作为预测疗效的敏感指标。 展开更多
关键词 肺肿瘤 T淋巴细胞亚群 炎症趋化因子类/血液 药物疗法 治疗结果
下载PDF
肿瘤相关巨噬细胞:调节肿瘤微环境的新靶点 被引量:1
17
作者 周银雪 任敦强 +4 位作者 毕焕焕 易冰倩 张彩 王红梅 孙家兴 《中国肺癌杂志》 CAS CSCD 北大核心 2024年第3期231-240,共10页
肿瘤相关巨噬细胞(tumor-associated macrophage,TAM)在肺癌免疫微环境中扮演着重要的角色。它们通过自身的表型和吞噬功能的变化,在肺癌的发生和进展中发挥作用,通过促进肺癌免疫抑制型微环境的形成和肿瘤异常血管的生长加速肺癌的侵... 肿瘤相关巨噬细胞(tumor-associated macrophage,TAM)在肺癌免疫微环境中扮演着重要的角色。它们通过自身的表型和吞噬功能的变化,在肺癌的发生和进展中发挥作用,通过促进肺癌免疫抑制型微环境的形成和肿瘤异常血管的生长加速肺癌的侵袭和扩散。巨噬细胞在应对不同刺激时,可以极化为具有不同功能和特征的亚型,分为抗肿瘤M1型和促肿瘤的M2型。在肿瘤组织中,TAM通常极化为交替活化型的M2表型,表现出对肿瘤免疫的抑制作用。本文综述了抗血管生成药物在调节TAM表型方面的作用,它们可以通过将M2型TAM重编程为M1型来发挥抗肿瘤作用。同时,TAM的功能改变在抗血管生成治疗和免疫治疗策略中也起到重要作用。研究证实,TAM通过极化及功能改变可能成为调节肿瘤微环境的新靶点,开辟肺癌治疗的新途径。 展开更多
关键词 肿瘤相关巨噬细胞 极化 抗血管生成治疗 肺肿瘤
下载PDF
可切除非小细胞肺癌新辅助免疫治疗研究进展 被引量:3
18
作者 齐畅 田攀文 李为民 《中国肺癌杂志》 CAS CSCD 北大核心 2024年第2期138-146,共9页
近年来,免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)对晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者预后的改善已成为共识,越来越多的临床研究也逐渐证明了免疫治疗对于可切除NSCLC患者的重要价值。然而,目前关... 近年来,免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)对晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者预后的改善已成为共识,越来越多的临床研究也逐渐证明了免疫治疗对于可切除NSCLC患者的重要价值。然而,目前关于新辅助治疗背景下免疫联合策略的探索、治疗相关副作用、预后生物标志物等问题仍存在争议。本文综述了可切除NSCLC患者新辅助免疫治疗的最新进展,引发了新的思考,并讨论了其在临床应用中的优势及挑战。 展开更多
关键词 肺肿瘤 新辅助治疗 免疫检查点抑制剂 围手术期 可切除非小细胞肺癌
下载PDF
驱动基因阴性非小细胞肺癌二线治疗中国专家共识 被引量:1
19
作者 中国临床肿瘤学会非小细胞肺癌专家委员会 周彩存 +4 位作者 王洁 程颖 王宝成 周清华 周斐 《中国肺癌杂志》 CAS CSCD 北大核心 2024年第2期81-87,共7页
对于驱动基因阴性的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者而言,既往化疗一直都是标准治疗选择,而免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)的加入为这部分患者提供了新的治疗选择。目前一线治疗可以选... 对于驱动基因阴性的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者而言,既往化疗一直都是标准治疗选择,而免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)的加入为这部分患者提供了新的治疗选择。目前一线治疗可以选择化疗、抗血管生成药物或免疫治疗。尽管初始治疗能获得一定的有效率,但仍不可避免地会出现疾病进展或治疗失败,二线及以上治疗疗效差,患者预后不佳,临床上需要更多有效的二线治疗药物。中国临床肿瘤学会非小细胞肺癌专家委员会组织呼吸科、肿瘤科、病理科专家对驱动基因阴性人群临床研究证据进行了深入探讨,根据专家组讨论后广泛认可的临床诊疗经验,对驱动基因阴性NSCLC患者二线治疗制定了统一的专家共识,可作为中国临床医师选择驱动基因阴性NSCLC二线治疗的指导依据。 展开更多
关键词 肺肿瘤 免疫治疗 抗血管生成药物 驱动基因阴性 专家共识
下载PDF
揿针联合穴位贴敷治疗对胃肠道肿瘤化疗患者胃肠道反应及睡眠质量的影响 被引量:1
20
作者 李胜楠 李亚 +2 位作者 张茜雯 李丽 申智慧 《山西医药杂志》 CAS 2024年第12期899-903,共5页
目的 探讨胃肠道肿瘤化疗患者应用揿针联合穴位贴敷治疗对胃肠道反应及睡眠质量的影响效果。方法 选择河南省肿瘤医院中西结合科住院的胃肠道肿瘤化疗患者96例(2021年10月至2023年6月入组)患者研究,参照计算机数字表法分为2组,每组48例... 目的 探讨胃肠道肿瘤化疗患者应用揿针联合穴位贴敷治疗对胃肠道反应及睡眠质量的影响效果。方法 选择河南省肿瘤医院中西结合科住院的胃肠道肿瘤化疗患者96例(2021年10月至2023年6月入组)患者研究,参照计算机数字表法分为2组,每组48例,包括对照组(穴位贴敷治疗)与试验组(揿针联合穴位贴敷治疗)。比较干预前后2组患者胃肠道反应及睡眠质量的变化。结果 治疗前,2组恶心程度评分、呕吐程度评分、食欲情况评分差异无统计学意义(P>0.05),治疗5 d、治疗7 d 2组均有改善,且试验组恶心程度评分、呕吐程度评分、食欲情况评分更低,差异有统计学意义(P<0.05);治疗7 d,试验组恶心频率与呕吐频率均低于对照组(P<0.05);治疗前,2组睡眠质量差异无统计学意义(P>0.05),治疗7 d试验组睡眠质量PSQI评分低于对照组(P<0.05);试验组总并发症发生率比对照组低(P<0.05)。结论 胃肠道肿瘤化疗患者应用揿针联合穴位贴敷治疗可以更好地减轻化疗所致的胃肠道反应,改善食欲及睡眠质量,值得应用。 展开更多
关键词 胃肠肿瘤 药物疗法 联合 胃肠道反应 揿针 穴位贴敷 食欲情况 睡眠质量
下载PDF
上一页 1 2 250 下一页 到第
使用帮助 返回顶部